Clinical study for NK cells in the treatment of severe endometriosis

NK cells therapy combined with conventional treatment for severe endometriosis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022201

Enrollment

Unknown

Registered

2019-03-30

Start date

2019-04-01

Completion date

Unknown

Last updated

2019-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

Experimental group:Conventional treatment and Autologous NK cells therapy

control group:Conventional treatment

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.Diagonsed as endometriosis stage III~IV; 2.Aged 18 to 45 years at the time of informed consent; 3.With indications for conservative endometriosis surgery; 4.With complete clinical data.

Exclusion criteria

Exclusion criteria: 1.Severe allergy to drugs; 2.Patients with abnormal immune status (Autoimmune disease or long-term use of immunosuppressive agents); 3.With serious cardiac, cerebrovascular diseases and liver, kidney disorders; 4.With a history of severe mental illness.

Design outcomes

Primary

Measure	Time frame
Immune indicators;Endocrine hormone levels;Clinical symptoms;Safety evaluation;	—

Countries

China

Contacts

Public ContactYi Yang

yiyang119@126.com+86 0755 22942466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026